tradingkey.logo

Neurocrine Reports Late Stage Data Of Crenessity

ReutersMay 8, 2025 1:04 PM

- Neurocrine Biosciences Inc NBIX.O:

  • NEUROCRINE BIOSCIENCES ANNOUNCES NEW RESULTS FROM EXPLORATORY ANALYSES OF THE PHASE 3 CAHTALYST™ PEDIATRIC STUDY DEMONSTRATING CRENESSITY™ REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING OR IMPROVING ANDROSTENEDIONE ACROSS PATIENT SUBGROUPS

  • NEUROCRINE BIOSCIENCES INC - CRENESSITY REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING ANDROSTENEDIONE LEVELS

  • NEUROCRINE BIOSCIENCES INC - DATA CONSISTENT ACROSS ALL PATIENT SUBGROUPS IN CAHTALYST STUDY

  • NEUROCRINE BIOSCIENCES INC - CRENESSITY GENERALLY WELL TOLERATED IN CAHTALYST STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI